NASDAQ: RVPHReviva Pharmaceuticals Holdings Inc Stock
$3.09+0.07 (+2.32%)
Updated Apr 22, 2024
RVPH Price
$3.09
Fair Value Price
$0.95
Market Cap
$86.27M
52 Week Low
$2.67
52 Week High
$9.25
P/E
-1.87x
P/B
15.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.14
Operating Cash Flow
-$28M
Beta
0.31
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RVPH Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RVPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVPH ($3.09) is overvalued by 225.63% relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RVPH ($3.09) is not significantly undervalued (225.63%) relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RVPH due diligence checks available for Premium users.
Be the first to know about important RVPH news, forecast changes, insider trades & much more!
RVPH News
Valuation
RVPH fair value
Fair Value of RVPH stock based on Discounted Cash Flow (DCF)
Price
$3.09
Fair Value
$0.95
Overvalued by
225.63%
RVPH ($3.09) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RVPH ($3.09) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RVPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.87x
Industry
16.21x
Market
41x
RVPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.09x
Industry
5.82x
RVPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.7M
Profit Margin
0%
Assets to liabilities
Assets
$23.7M
Liabilities
$18.0M
Debt to equity
3.14
RVPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
$0.0
Financing
$27.3M
RVPH vs Biotech Stocks
Reviva Pharmaceuticals Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.